Earnings
Stoke CEO: FDA Never Raised An Advisory Committee, And Five-Year Data Is A 'Review Issue'
Stoke plans to feed data to the FDA through the first half of 2027, with $358.8 million in cash expected to last into early 2028.
STOK
Stoke Therapeutics (STOK) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Stoke Says FDA Is 'Willing To Accept' A Combined Cognition Score For Its Dravet Drug
The company plans to file in the second half of 2027 after a third-quarter 2027 readout, and it expects no advisory committee.
Earnings
Stoke Therapeutics Loses $73.6 Million In The Quarter As Dravet Drug Spending Climbs
The biotech still targets a third-quarter 2027 readout for its Dravet trial and says $358.8 million in cash lasts into early 2028.